Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01261065 · ClinicalTrials.gov registry record · Phase 4
Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
A Phase 4 study of Heart Failure and Cardiomyopathy, sponsored by Michael E. DeBakey VA Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT01261065: Completed Phase 4 study of Heart Failure and Cardiomyopathy, sponsored by Michael E. DeBakey VA Medical Center.
NCT01261065 is a Phase 4 study of Heart Failure and Cardiomyopathy that has completed, run by Michael E. DeBakey VA Medical Center. The registered enrollment target is 55 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01261065, a Phase 4 study of Heart Failure and Cardiomyopathy, has completed, sponsored by Michael E. DeBakey VA Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall hypothesis of this application is that the improvement in LV ejection performance following treatment with betablockers is due, at least in part, to improvement in intrinsic myocardial contractility.
Primary Outcome
Mean velocity of circumferential fiber shortening (VCF) will be derived as = Left Ventricular Fractional shortening / Ejection Time.Left ventricular (LV) end-systolic stress will be calculated as = (\[1.35 × P × LV endsysolic diameter\]/(4 × LV posterior wall thickness in systole × (1+LV posterior wall thickness in systole /LV endsysolic diameter)))
Conditions Studied
Interventions
- DRUG carvedilol
Study Locations (1)
Texas
- Michael E. DeBakey Veterans Affairs Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2001-12 |
| Est. Completion | 2005-10 |
| Phase | Phase 4 |
What the finished NCT01261065 record still lists
NCT01261065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which carvedilol is the first listed.
NCT01261065 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01261065 about?
NCT01261065 is a clinical study titled "Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure". The overall hypothesis of this application is that the improvement in LV ejection performance following treatment with betablockers is due, at least in part, to improvement in intrinsic myocardial contractility.
What is the current status of trial NCT01261065?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2001-12. Estimated completion is 2005-10.
What conditions does trial NCT01261065 study?
This clinical trial studies the following conditions: Heart Failure, Cardiomyopathy.
What interventions are being tested in trial NCT01261065?
The interventions under investigation include: carvedilol (DRUG).
Who is sponsoring clinical trial NCT01261065?
This trial is sponsored by Michael E. DeBakey VA Medical Center, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01261065 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01261065's enrollment target sits among peer trials
55 273rd of 397 higher than 124 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia